Table 2. Summary of the meta-analysis of thromboprophylaxis efficacy following CS.
| Subgroup | Included studies | N | RR (95% CI) | I2 (%) | P (%) |
|---|---|---|---|---|---|
| LMWH versus negative control | Overall | 5 | 1.18(0.28–4.91) | 0 | 0.82 |
| RCTs | 4 | 1.18(0.28–4.91) | 0 | 0.82 | |
| Cohort | 1 | NE | NA | NA | |
| Unknown risk of VTE | 5 | 1.18(0.28–4.91) | 0 | 0.82 | |
| LMWH versus UFH | Overall | 2 | 0.33(0.01–7.99) | NA | 0.50 |
| RCTs | 1 | 0.33(0.01–7.99) | NA | 0.50 | |
| Unknown risk of VTE | 1 | 0.33(0.01–7.99) | NA | 0.50 | |
| High risk of VTE | 1 | NE | NA | NA | |
| LMWH versus LMWH | Overall | 3 | NE | NA | NA |
| RCTs | 3 | NE | NA | NA | |
| High risk of VTE | 3 | NE | NA | NA |
Abbreviations: N, number of studies; RR, risk ratios; CI, confidence interval; P, P value for association; NE, not estimable; NA, not applicable.